Biotech News
Cytokinetics to Participate in November Investor Conferences
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in November:
Related news
Cytokinetics
Muscle Biology Specialization Cytokinetics develops and commercializes medicines that modulate muscle function. Its portfolio is centered on cardiac muscle biology and diseases in which altered contractility contributes directly to symptoms and clinical outcomes. MYQORZO in Obstructive HCM MYQORZO, or aficamten, is a cardiac myosin...
Recent company news
CYTKCytokinetics2026-11-03 21:00 EST
Cytokinetics to Participate in November Investor Conferences
CYTKCytokinetics2026-11-02 12:30 EST
Cytokinetics Announces Three Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026
CYTKCytokinetics2026-10-21 20:00 EST
Cytokinetics to Announce Third Quarter Results on November 4, 2026
CYTKCytokinetics2026-10-19 20:00 EST
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CYTKCytokinetics2026-10-19 11:30 EST
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Stock data
- Close
- 55.55 USD
- Market cap
- 9.63B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States